

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
CB Biotech Investment Ltd			2/2/2016		BeiGene, Ltd. [BGNE]		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
C/O MAPLES CORPORATE SERVICES LIMITED, KINGSTON CHAMBERS, P.O. BOX 173			<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)				
(Street)			5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)		
ROAD TOWN, TORTOLA, D8 VG1110					<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Shares	(1)	(1)	Ordinary Shares	14814814 (2)	(1)	D	
Series A-2 Preferred Shares	(3)	(3)	Ordinary Shares	4786324 (2)	(3)	D	

Explanation of Responses:

- These securities consist of Series A Preferred Shares (the "Series A Shares") of the Issuer, which are convertible at any time into the Issuer's Ordinary Shares and will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series A Shares do not have an expiration date.
- CB Biotech Investment Limited ("CB Biotech") directly owns 14,814,814 Series A Shares and 4,786,324 Series A-2 Preferred Shares (the "Series A-2 Shares"). CB Biotech is wholly owned by CPEChina Fund, L.P. ("CPEC"), and CITIC PE Associates, L.P. ("PE Associates") is the sole general partner of CPEC. CITIC PE Funds Limited ("PE Funds") is the sole general partner of PE Associates. The shares directly owned by CB Biotech may be deemed indirectly owned by CPEC, PE Associates and PE Funds (the "Reporting Persons"); however, each Reporting Person disclaims beneficial ownership of these securities except to the extent of its respective pecuniary interest therein, if any, and the inclusion of these shares in their report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or any other purpose.
- These securities consist of the Series A-2 Shares of the Issuer, which are convertible at any time into the Issuer's Ordinary Shares and will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series A-2 Shares do not have an expiration date.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CB Biotech Investment Ltd C/O MAPLES CORPORATE SERVICES LIMITED KINGSTON CHAMBERS, P.O. BOX 173 ROAD TOWN, TORTOLA, D8 VG1110		X		
CPEChina Fund, L.P. C/O MAPLES CORPORATE SERVICES LIMITED KINGSTON CHAMBERS, P.O. BOX 173 ROAD TOWN, TORTOLA, D8 VG1110		X		
CITIC PE Associates, L.P. C/O MAPLES CORPORATE SERVICES LIMITED KINGSTON CHAMBERS, P.O. BOX 173 ROAD TOWN, TORTOLA, D8 VG1110		X		
CITIC PE Funds Ltd C/O MAPLES CORPORATE SERVICES LIMITED KINGSTON CHAMBERS, P.O. BOX 173 ROAD TOWN, TORTOLA, D8 VG1110		X		

Signatures**CB Biotech Investment Limited /s/ Ching Nar Cindy Chan****2/2/2016**

—Signature of Reporting Person

Date

CPEChina Fund, L.P. /s/ Ching Nar Cindy Chan**2/2/2016**

—Signature of Reporting Person

Date

CITIC PE Associates, L.P. /s/ Ching Nar Cindy Chan**2/2/2016**

—Signature of Reporting Person

Date

CITIC PE Funds Limited /s/ Ching Nar Cindy Chan**2/2/2016**

—Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitute and appoint each of Howard Liang and Qing Nian, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or ten percent (10%) or greater shareholder of BeiGene, Ltd. (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedule 13D and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or any amendment(s) thereto, and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grant to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledge that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agree to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of, or legal counsel to, the Company.

IN WITNESS WHEREOF, the undersigned have caused this Power of Attorney to be executed as of February 2, 2016.

CB Biotech Investment Limited

By: /s/ Ching Nar Cindy Chan

Name: Ching Nar Cindy Chan

Title: Director

CPEChina Fund, L.P.

By: /s/ Ching Nar Cindy Chan

Name: Ching Nar Cindy Chan

Title: Director

CITIC PE Associates, L.P.

By: /s/ Ching Nar Cindy Chan

Name: Ching Nar Cindy Chan

Title: Director

CITIC PE Funds Limited

By: /s/ Ching Nar Cindy Chan

Name: Ching Nar Cindy Chan

Title: Director
